XML 104 R84.htm IDEA: XBRL DOCUMENT v3.6.0.2
Segment and Geographic Information Segment and Geographic Information (Details) - USD ($)
 3 Months Ended 12 Months Ended
Dec. 31, 2016
Sep. 30, 2016
Jun. 30, 2016
Mar. 31, 2016
Dec. 31, 2015
Sep. 30, 2015
Jun. 30, 2015
Mar. 31, 2015
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Segment Reporting Information [Line Items]                      
Concentration Risk, Credit Risk, Financial Instrument, Maximum Exposure                 $ 98,919    
Asset impairments                 1,217,000 $ 253,560,000 $ 0
Asset Impairments Charges and Other PP&E Impairment                 1,217,000 255,116,000 0
Sales to external customers                 859,154,000 1,040,160,000 1,192,952,000
Depreciation and amortization expense                 37,509,000 45,448,000 43,176,000
Operating income (loss) (2)(5) $ 2,332,000 $ 20,064,000 $ 34,939,000 $ 37,000 $ (238,918,000) $ 15,609,000 $ 25,129,000 $ 14,957,000 57,372,000 [1],[2] (183,223,000) [3],[4] 138,157,000
Total assets (3) 1,233,082,000       1,200,140,000       1,233,082,000 1,200,140,000 1,459,517,000
Capital expenditures                 17,785,000 47,039,000 62,135,000
Escrow Settlement                     5,003,000
Segments, Geographical Areas [Abstract]                      
Property, plant and equipment, net 251,049,000       266,277,000       251,049,000 266,277,000  
United States [Member]                      
Segment Reporting Information [Line Items]                      
Sales to external customers                 425,985,000 513,691,000 560,846,000
Segments, Geographical Areas [Abstract]                      
Property, plant and equipment, net 145,014,000       153,987,000       145,014,000 153,987,000  
CZECH REPUBLIC                      
Segments, Geographical Areas [Abstract]                      
Property, plant and equipment, net 18,454,000       19,742,000       18,454,000 19,742,000  
China [Member]                      
Segment Reporting Information [Line Items]                      
Sales to external customers                 147,720,000 109,978,000 188,047,000
Segments, Geographical Areas [Abstract]                      
Property, plant and equipment, net 75,409,000       79,691,000       75,409,000 79,691,000  
Germany [Member]                      
Segments, Geographical Areas [Abstract]                      
Property, plant and equipment, net 11,572,000       12,246,000       11,572,000 12,246,000  
Other Non-U.S. Countries [Member]                      
Segment Reporting Information [Line Items]                      
Sales to external customers                 285,449,000 416,491,000 444,059,000
Segments, Geographical Areas [Abstract]                      
Property, plant and equipment, net 600,000       611,000       600,000 611,000  
Non-U.S. Countries [Member]                      
Segment Reporting Information [Line Items]                      
Sales to external customers                 433,169,000 526,469,000 632,106,000
Segments, Geographical Areas [Abstract]                      
Property, plant and equipment, net 106,035,000       112,290,000       106,035,000 112,290,000  
Energy & Chemicals [Member]                      
Segment Reporting Information [Line Items]                      
Asset Impairments Charges and Other PP&E Impairment                   68,796,000  
Sales to external customers                 154,249,000 330,968,000 388,018,000
Depreciation and amortization expense                 9,984,000 11,805,000 9,649,000
Operating income (loss) (2)(5)                 13,307,000 (10,050,000) 78,006,000
Total assets (3) 177,514,000       251,810,000       177,514,000 251,810,000 322,936,000
Capital expenditures                 3,316,000 4,074,000 24,834,000
Energy & Chemicals [Member] | Natural gas processing (including petrochemical) applications [Member]                      
Segment Reporting Information [Line Items]                      
Sales to external customers                 105,372,000 180,909,000 208,706,000
Energy & Chemicals [Member] | Liquefied natural gas applications [Member]                      
Segment Reporting Information [Line Items]                      
Sales to external customers                 38,184,000 136,049,000 143,870,000
Energy & Chemicals [Member] | Industrial gas applications [Member]                      
Segment Reporting Information [Line Items]                      
Sales to external customers                 10,693,000 14,010,000 35,442,000
Distribution & Storage [Member]                      
Segment Reporting Information [Line Items]                      
Asset Impairments Charges and Other PP&E Impairment                 1,217,000 2,020,000  
Sales to external customers                 497,137,000 487,557,000 578,806,000
Depreciation and amortization expense                 18,432,000 18,289,000 16,749,000
Operating income (loss) (2)(5)                 50,435,000 39,549,000 82,612,000
Total assets (3) 657,599,000       689,112,000       657,599,000 689,112,000 666,451,000
Capital expenditures                 11,706,000 36,835,000 29,583,000
Distribution & Storage [Member] | Liquefied natural gas applications [Member]                      
Segment Reporting Information [Line Items]                      
Sales to external customers                 109,806,000 115,909,000 209,626,000
Distribution & Storage [Member] | Bulk industrial gas applications [Member]                      
Segment Reporting Information [Line Items]                      
Sales to external customers                 227,650,000 203,834,000 204,214,000
Distribution & Storage [Member] | Packaged gas industrial applications [Member]                      
Segment Reporting Information [Line Items]                      
Sales to external customers                 159,681,000 167,814,000 164,966,000
BioMedical [Member]                      
Segment Reporting Information [Line Items]                      
Asset Impairments Charges and Other PP&E Impairment                   184,300,000  
Sales to external customers                 207,768,000 221,635,000 226,128,000
Depreciation and amortization expense                 5,953,000 12,039,000 13,842,000
Operating income (loss) (2)(5)                 41,967,000 (165,336,000) 25,009,000 [5]
Total assets (3) 178,747,000       224,443,000       178,747,000 224,443,000 396,320,000
Capital expenditures                 2,303,000 3,849,000 3,484,000
BioMedical [Member] | Respiratory therapy [Member]                      
Segment Reporting Information [Line Items]                      
Sales to external customers                 118,926,000 132,321,000 141,273,000
BioMedical [Member] | Life sciences [Member]                      
Segment Reporting Information [Line Items]                      
Sales to external customers                 70,572,000 64,641,000 65,948,000
BioMedical [Member] | Commercial oxygen generation [Member]                      
Segment Reporting Information [Line Items]                      
Sales to external customers                 18,270,000 24,673,000 18,907,000
Corporate [Member]                      
Segment Reporting Information [Line Items]                      
Sales to external customers                 0 0 0
Depreciation and amortization expense                 3,140,000 3,315,000 2,936,000
Operating income (loss) (2)(5)                 (48,337,000) (47,386,000) (47,470,000)
Total assets (3) [6] $ 219,222,000       $ 34,775,000       219,222,000 34,775,000 73,810,000
Capital expenditures                 460,000 2,281,000 $ 4,234,000
Cost of Sales [Member]                      
Segment Reporting Information [Line Items]                      
Asset impairments                   $ 1,556,000  
Cost of Sales [Member] | BioMedical [Member]                      
Segment Reporting Information [Line Items]                      
Gain (Loss) Related to Litigation Settlement                 15,145,000    
Selling, General and Administrative Expenses [Member] | BioMedical [Member]                      
Segment Reporting Information [Line Items]                      
Gain (Loss) Related to Litigation Settlement                 $ 376,000    
[1] (1) During the third quarter of 2016, the Company recovered for breaches of representations and warranties primarily related to warranty costs for certain product lines acquired in the 2012 acquisition of AirSep under the related representation and warranty insurance. For the year ended December 31, 2016, this reduced BioMedical segment’s cost of sales by $15,145 and Corporate SG&A expenses by $376, net of associated legal fees recorded in 2016. The 2016 operating income also includes asset impairment charges of $1,217 attributed to D&S.
[2] The 2016 operating income also includes impairment of goodwill and intangible assets totaling $1,217 as described in Note 3, Asset Impairments, to the consolidated financial statements.
[3] (1) Includes impairment of goodwill and intangible assets totaling $253,560 as described in Note 3, Asset Impairments, to the consolidated financial statements.
[4] Includes asset impairment charges of $255,116 for the year ended December 31, 2015, attributed to E&C - $68,796, D&S - $2,020, and BioMedical - $184,300.
[5] The BioMedical segment’s operating income included recovery of $5,003 increasing operating income for the year ended December 31, 2014 from an escrow settlement for breaches of representations and warranties relating to warranty costs (which are in excess of the settlement amount) for certain product lines acquired from AirSep in 2012.
[6] Corporate assets consist primarily of cash, cash equivalents, and deferred income taxes.